| Schedule of Provision for Income Taxes |
Our
provision (benefit) for income taxes for the years ended December 31, 2022 and 2021 was as follows:
Schedule of Provision for Income Taxes
| |
|
2022 |
|
|
2021 |
|
| |
|
Year Ended December 31, |
|
| |
|
2022 |
|
|
2021 |
|
| Current: |
|
|
|
|
|
|
|
|
| Federal |
|
$ |
- |
|
|
$ |
- |
|
| State |
|
|
- |
|
|
|
- |
|
| Total deferred tax benefit |
|
|
- |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
| Deferred: |
|
|
|
|
|
|
|
|
| Federal |
|
|
(5,887,151 |
) |
|
|
(2,853,937 |
) |
| State |
|
|
(1,567,560 |
) |
|
|
(624,844 |
) |
| Total deferred tax benefit |
|
|
(7,454,711 |
) |
|
|
(3,478,781 |
) |
| |
|
|
|
|
|
|
|
|
| Valuation allowance |
|
|
7,454,711 |
|
|
|
2,948,170 |
|
| Net deferred tax benefit |
|
|
- |
|
|
|
(530,611 |
) |
| |
|
|
|
|
|
|
|
|
| Total tax provision (benefit) |
|
$ |
- |
|
|
$ |
(530,611 |
) |
|
| Schedule of Effective Income Tax Rate Reconciliation |
A
reconciliation of our effective income tax rate and statutory income tax rate for the years ended December 31, 2022 and 2021 is as follows:
Schedule of Effective Income Tax Rate Reconciliation
| |
|
2022 |
|
|
2021 |
|
| |
|
Year Ended December 31, |
|
| |
|
2022 |
|
|
2021 |
|
| Federal statutory income tax rate |
|
|
21.00 |
% |
|
|
21.00 |
% |
| State tax rate, net |
|
|
5.72 |
% |
|
|
5.23 |
% |
| Permanent differences |
|
|
(0.55 |
)% |
|
|
(0.18 |
)% |
| Federal orphan drug tax credit |
|
|
0.93 |
% |
|
|
3.04 |
% |
| Deferred tax asset valuation allowance |
|
|
(27.10 |
)% |
|
|
(24.65 |
)% |
| |
|
|
|
|
|
|
|
|
| Effective income tax rate |
|
|
0.00 |
% |
|
|
4.44 |
% |
|
| Schedule of Deferred Tax Assets and Liabilities |
The
significant components of our deferred tax assets and liabilities for Federal and state income taxes consisted of the following:
Schedule of Deferred Tax Assets and Liabilities
| |
|
2022 |
|
|
2021 |
|
| |
|
December 31, |
|
| |
|
2022 |
|
|
2021 |
|
| Deferred tax assets: |
|
|
|
|
|
|
|
|
| Non-current: |
|
|
|
|
|
|
|
|
| Net operating loss carry forward – Federal |
|
$ |
5,048,175 |
|
|
$ |
2,615,518 |
|
| Net operating loss carry forward – State |
|
|
1,431,839 |
|
|
|
760,897 |
|
| Stock compensation expense |
|
|
2,590,890 |
|
|
|
593,365 |
|
| Depreciation and other |
|
|
976 |
|
|
|
13,200 |
|
| Purchased in-process R&D |
|
|
2,494,829 |
|
|
|
2,481,070 |
|
| Federal orphan drug credits |
|
|
1,046,539 |
|
|
|
791,151 |
|
| Capitalized research and development costs |
|
|
1,929,462 |
|
|
|
- |
|
| Start-up expenditures and amortization |
|
|
- |
|
|
|
1,978,418 |
|
| Total non-current deferred tax assets |
|
|
14,542,710 |
|
|
|
9,233,619 |
|
| Valuation allowance for deferred tax assets |
|
|
(14,542,710 |
) |
|
|
(7,087,999 |
) |
| Total deferred tax assets |
|
|
- |
|
|
|
2,145,620 |
|
| |
|
|
|
|
|
|
|
|
| Deferred Tax Liabilities: |
|
|
|
|
|
|
|
|
| Non-current: |
|
|
|
|
|
|
|
|
| Intangible asset |
|
|
- |
|
|
|
(2,145,620 |
) |
| Total non-current deferred tax liabilities |
|
|
- |
|
|
|
(2,145,620 |
) |
| |
|
|
|
|
|
|
|
|
| Total deferred tax asset (liability) |
|
$ |
- |
|
|
$ |
- |
|
|